SAN FRANCISCO — The First District Court of Appeal has affirmed a $400 million judgment against a Swiss pharmaceutical company for using a corporate acquisition to snuff out a competitor’s potentially lifesaving drug.
Justice Terence Bruiniers led a unanimous panel upholding the award, which includes $30 million in punitive damages against three individual company executives. Jurors could have reasonably concluded that leaders of Actelion Pharmaceuticals “sabotaged” the development of fasudil, “a drug with the potential for alleviating the suffering of patients with life-threatening and debilitating diseases from reaching the market,” Bruiniers wrote.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
